drugset / Trial / NCT07548840

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT07548840

Phase 3 Recruiting 30 enrolled Taisho Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on hemodialysis

Timeline

Start
2026-05-08
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral
Subject TS-172 Unknown 60 mg Oral

Indications